Tracing the Scientific Breakthroughs Behind AKNETIDE®

AKNETIDE® R&D has been grounded over a decade of research from molecular discovery to clinical validation. Below is a snapshot of key scientific and regulatory milestones that demonstrate its journey from lab bench to real-world acne care efficacy.

2014

Inception of AMP

Inception of antimicrobial peptide discovery from nature and lab development

2019

Granted the world first ever AMP additive for animal nutrition and health

Granted the world first-ever antimicrobial peptide zootechnical additive for animal nutrition

2023

The cyclopeptide was discovered

AKNETIDE®, a novel antimicrobial cyclopeptide with potent inhibition against C. acne and S. aureus, was discovered

2024

First clinical study by SGS

The first-ever clinical study, with SGS Cosmetic Lab, was completed and demonstrated the significant efficacy of sensible acne level alleviation

2025

Multi-MOAs established and a strict hospital clinical study completed

Mechanism Elucidation: Multi-MOAs were established and proven by a leading cosmetic research institute

A double-blinded placebo-controlled Clinical Study in a world-famous Dermatology Hospital was conducted.

Scientifically proven and Dermatologist Endorsed evidences behind AKNETIDE®

Backed by 10+ years of rigorous consistent research of antimicrobial bioactive peptides, and recently validated by leading independent biochemical laboratories and top-tier dermatology hospital, AKNETIDE® harvested myriads of evidences, either of mechanism or of clinical studies, enables it deserving a worldwide breakthrough anti acne cosmetic ingredient designed for EFFICACY without bragging.

Double-Blind Hospital Study

A dermatology hospital clinical study. A 7-day double-blinded placebo-controlled clinical study demonstrated the prototype formula embedded ANKENTIDE® efficacious in alleviating acne and improving skin conditions of volunteers

SGS Clinical Study

AKNETIDE® embedded prototype formula demonstrated potent efficacy in significantly alleviating volunteers’ acne conditions from black heads to papules in 7 days.

View Study

In-vitro Safety Studies

Skin irritation, phototoxicity, eye irritation, sensitization to skin were all tested NEGATIVE;  HaCaT MTT Toxicity data was given.

View Study

Published Studies and Patents

To be published shortly…

A start-up company delivering AKNETIDNE®, a first-in-class Anti-acne Antimicrobial Cyclopeptide with COSMOS Approved

Quick Links

  • Acne Vulgaris
  • Mainstream Anti-Acne
  • AKNETIDE
  • Science & Evidence
  • Colaboration Exploration

Contact Details

Whatsapp Linkedin
2025 © All Rights Reserved

Disclaimers

The number of blackheads, total acne, papules and pustules were reduced by 88.7%, 16.3%, 51.0% and 13.6% respectively within 7 days since application of AKENTIDE as the only bioactive ingredient in the cosmetic serum sample.